Who Qualifies for Ozempic?

Ozempic is approved for adults with type 2 diabetes to improve blood sugar control. Physicians also prescribe it off-label for weight loss in people without diabetes. The eligibility criteria differ depending on whether your goal is diabetes management or weight reduction, and which version of semaglutide your physician prescribes.

Understanding who qualifies helps set realistic expectations before approaching a physician about GLP-1 treatment.

Ozempic for Type 2 Diabetes

The primary approved indication for Ozempic is type 2 diabetes in adults. Eligibility requires a confirmed type 2 diabetes diagnosis. It is used when blood sugar is not adequately controlled by metformin alone or when a physician determines that a GLP-1 receptor agonist is appropriate for a patient's metabolic profile.

There is no specific BMI requirement for diabetes-related prescribing. However, overweight or obese patients with type 2 diabetes benefit from both the blood sugar improvement and the weight loss effect simultaneously.

Wegovy for Obesity (Without Diabetes)

Wegovy — the higher-dose semaglutide — is approved specifically for chronic weight management. The eligibility criteria are:

• BMI of 30 or higher (obesity), or
• BMI of 27 or higher plus at least one weight-related health condition: high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea

These BMI thresholds were set for the general population and are based on European population risk data.

The South Asian BMI Adjustment

Standard BMI thresholds underestimate metabolic risk in South Asian populations, including Pakistanis. Research consistently shows that South Asian adults develop insulin resistance, visceral fat accumulation, and cardiovascular risk at lower BMI values than European populations.

Many physicians working with South Asian patients use adjusted criteria: BMI of 27.5 or higher for consideration, rather than 30. Some use waist circumference as a primary measure rather than BMI. A waist measurement above 80 cm for South Asian women and above 90 cm for South Asian men indicates elevated metabolic risk regardless of overall BMI.

Calculate your BMI to know your starting number, then discuss adjusted thresholds with your physician.

Who Should Not Use Ozempic

Ozempic has several firm contraindications:

Personal or family history of medullary thyroid carcinoma (MTC): The GLP-1 receptor is present on thyroid C-cells. Animal studies showed increased thyroid tumour risk with semaglutide. Human evidence has not confirmed this risk, but the black-box warning means people with MTC history or Multiple Endocrine Neoplasia type 2 (MEN2) should not use it.

Pregnancy or breastfeeding: Semaglutide is not approved during pregnancy. Animal studies showed foetal harm. Women who become pregnant during treatment should discontinue immediately.

Severe gastrointestinal disease: Conditions like gastroparesis are worsened by semaglutide's gastric-emptying slowdown. Active inflammatory bowel disease may also be contraindicated.

Type 1 diabetes: GLP-1 receptor agonists are not approved for type 1 diabetes management.

Pancreatitis history: There is a possible association between GLP-1 drugs and pancreatitis. People with a history of pancreatitis require careful physician evaluation before prescribing.

If You Cannot Access Ozempic in Pakistan

For Pakistani adults who need GLP-1 metabolic support but cannot access pharmaceutical semaglutide, METASLIM is a DRAP-registered alternative. It provides GLP-1 pathway support through sublingual drops in a physician-guided 8-week program — available to Pakistani adults without the prescribing barriers that pharmaceutical GLP-1 drugs face in this market.